Pulmonary Hypertension Flashcards Preview

PMPR 430 > Pulmonary Hypertension > Flashcards

Flashcards in Pulmonary Hypertension Deck (29)
Loading flashcards...
1
Q

How is pulmonary hypertension

A

Increase in mean pulmonary arterial pressure greater than 25 mmHg OR 30 mmHg with exercise

2
Q

What are the diagnostic classifications for pulmonary hypertension in neonates

A

Prenatal or developmental, persistent pulmonary hypertension of the newborn, pediatric heart disease, bronchopulmonary dysplasia, isolated pulmonary arterial hypertension, pediatric lung disease

3
Q

What are the world health organization functional classification of pulmonary hypertension

A

Class 1: No limitations of physical activity, Class 2: slight limitations of physical activity but comfortable at rest, Class 3:marked limitations of physical activity but comfortable at rest, Class 4: symptoms at rest

4
Q

What are the functional classifications for pulmonary hypertension in children

A

Class 1: Asymptomatic growing and developing normally with no limitation to activity, Class 2: slight limitation to activity with delayed developmental milestones while comfortable at rest, Class 3A: Marked limitation to activity with regression of learned physical activities with frequent naps compromised comfortability at rest, 3B: The growth is severly compromised with supplemental feelings required, Class 4: unable to do any physical activity and not able to interact with family

5
Q

What are signs and symptoms of pulmonary hypertension

A

Low oxygen saturation, failure to thrive, lethargic, tachypnea, tachycardia, peripheral edema

6
Q

What is the pathophysiology of PPHN

A

Failure to achieve normal drop in Pulmonary vascular resistance, decreased/dysfunctional endothelial nitric oxide synthase (eNOS)

7
Q

What is the treatment for PPHN

A

Inhaled nitric oxide (dilates vessels in the lungs)/ prostacylcin anaglos or sildenafil

8
Q

What is the pathophysiology in pediatrics

A

Relative imbalances of mediator substances that causes vasoconstriction, pulmonary vscular remodeling and thrombosis

9
Q

What are mediator substances that are increased in pediatric pulmonary hypertension, decreased

A

Endothelin-1, thromboxane A2, endothelin 1/ prostacyclin and nitric oxide

10
Q

What are the adjunctive therapies that can be used to treat pulmonary hypertension

A

oxygen, diuretics, and calcium channel blockers, vasopressors, sedation and NMBAs, warfarin

11
Q

What are the potential therapies for pulmonary hypertension

A

inhaled nitric oxide (iNO), prostacyclin analogs, endothelian-1 antagonist, phosphodiesterase inhibitors

12
Q

What is the MOA of prostacyclin

A

Bind smooth muscles in the vasculature causing vasodilation and anti-proliferation

13
Q

What are the prostacyclin analogs duration

A

Epoprostenol treprostinil, Iloprost

14
Q

What is the problem with using epopstenol in pulmonary hypertension

A

Continous IV infusion (requires long term central venous catheter), not selective and causes vast hypotension

15
Q

What are other side effects

A

flushing headache nausea diarrhea tachycardia pain tachyphylaxis

16
Q

What are the dosage forms of treprostinil, side effects

A

Continous subcutaneous infusion, continous IV infusion, inhaled dosage form/ pain and erythema upon injection site

17
Q

Which is the most pulmonary selective, drawback

A

Iloprost, requires 6 to 9 inhalations

18
Q

T/F: Endothelin 1 causes vasconstriction in the pulmonary vasculature depending on the receptor that is bound

A

True

19
Q

Where is endothelian A receptors located, what do they cause

A

Smooth muscle cell/ vasoconstriction, proliferation, cell migration, hypertrophy

20
Q

Where is endothelian B receptors located, what do they cause

A

Endothelial cells/ inhibition of endothelian 1 production, increased clearance of endothelian 1, increased production of nitrous oxide and PGI2, increased vaso-dilation and anti-proliferation

21
Q

What are the endothelian 1 receptor antagonists

A

Bosentan and Ambrisentan

22
Q

Which endothelian 1 receptor is contranindicated in pregnancy and has drug-drug interactions, what are the liver enzymes that cause interactions

A

Bosentan/ CYP2C9: warfarin and oral contraceptives, CYP3A4: ketoconazole, fluvastin, itraconazole

23
Q

What is required for using Bosentan, what changes must be done due to this requirement

A

Monthly monitoring of LFTs/ If greater than 3 and less than 5 times the upper normal limit: lower the dose for discontinue and monitor every 2 weeks, If greater than 5 and less than 8 times the upper normal limit: stop the bosentan and monitor for two weeks (can re-consider), If greater than 8 times the upper normal limit: Stop bosentan and do not reintroduce

24
Q

What is the pedatric dosing for bosentan

A

Less than 10kg: 1-2 mg/kg/dose, Greater than or equal to 10kg: 31.25 mg- 62.5 mg once or twice a day

25
Q

How should bosentan be administrated

A

Wear mask so to not risk teratogenic risk to fetus, should NOT be crushed, dissolve tablets in water just prior to use

26
Q

Which endothelian receptor antagonist that is specific to endothelian receptor 1, other advantage, side effects

A

Ambrisentan, no hepatic toxicity/ nasal congestion, headache, flushing

27
Q

What are the phosphodiesterase 5 inhibitors used to treat pulmonary hypertension

A

Sildenafil and Tadalafil

28
Q

What is the MOA of PDE5- inhibitors

A

Prevent’s cGMP from being broken down by PDE

29
Q

What are the benefits of using sildenafil

A

lower pulmonary vascular resistance, increase exercise tolerance, available IV (intermittent)